Go back

Universities welcome EU pharma strategy’s support for research

Industry representatives complain strategy ‘weakens incentives for innovation’

Universities have welcomed plans to support drug R&D in the European Commission’s pharmaceutical strategy for Europe, but industry representatives have complained that in some respects it “weakens incentives for innovation”.

The Guild of European Research-Intensive Universities said research and innovation are “key components of the pharmaceutical value chain” and that it “strongly supports the pharmaceutical strategy’s acknowledgement of the importance of investment in this area and the planned support” through the EU’s 2021-27 R&D and health programmes, Horizon Europe and EU4Health.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.